http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0401238-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
filingDate 2002-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5945f6ec2200deb3ec52899bc97805b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_534683b566711b79535c693927381403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21919fca0cb6b6112cc5407051b50768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f31656c8a45814bf5646196f9322d9dd
publicationDate 2004-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber HU-0401238-A2
titleOfInvention A pharmaceutical dosage form and method for producing amorphous nelfinavir mesylate
abstract The amorphous nelfinavir mesylate solid dosage unit form of the invention comprises amorphous nelfinavir mesylate and a pharmaceutically acceptable, water-soluble, nonionic block copolymer of ethylene oxide and propylene oxide having a melting point of at least 40 ° C. The invention further relates to a wet melt granulation process for the preparation of the above dosage form. SHE
priorityDate 2001-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538474
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57503849
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6354
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64143
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6378
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451253995
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504556
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415729217
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416604284
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64142
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60542
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451905405

Total number of triples: 41.